Eli Lilly plans to price fixed-rate notes in four tranches

By Devika Patel

Knoxville, Tenn., Feb. 20 – Eli Lilly & Co. plans to sell four tranches of dollar-denominated fixed-rate notes, according to a 424B2 filing with the Securities and Exchange Commission.

One tranche of notes has a make-whole call. The remaining three tranches have a make-whole call and then a par call.

Deutsche Bank Securities Inc., Barclays, BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are the bookrunners.

Proceeds will be used to repay commercial paper issued in connection with the company’s approximately $8 billion acquisition of Loxo Oncology, Inc. and for general corporate purposes.

Eli Lilly is an Indianapolis-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.